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Abstract 1 
In clinical practice, deep brain stimulation (DBS) is effective for treatment of motor 2 
symptoms in Parkinson’s disease (PD). However, the mechanisms have not been 3 
understood completely. There are some reports that electrical stimulation exerts 4 
neuroprotective effects on the central nervous system diseases including cerebral 5 
ischemia, head trauma, epilepsy and PD, although there are a few reports on 6 
neuroprotective effects of spinal cord stimulation (SCS). We investigated the 7 
neuroprotective effects of high cervical SCS on PD model of rats. Adult female 8 
Sprague-Dawley rats received hour-long SCS (2, 50 or 200Hz) with an epidural 9 
electrode at C1-2 level for 16 consecutive days. At 2 days after initial SCS, 10 
6-hydroxydopamine (6-OHDA) was injected into the right striatum of rats. Behavioral 11 
evaluations of PD symptoms were employed, including cylinder test and 12 
amphetamine-induced rotation test performed at 1 and 2 weeks after 6-OHDA injection. 13 
Animals were subsequently euthanized for immunohistochemical investigations. In 14 
order to explore neurotrophic and growth factor upregulation induced by SCS, another 15 
cohort of rats that received 50Hz SCS was euthanized at 1 and 2 weeks after lesion for 16 
protein assays. Behavioral tests revealed that the number of amphetamine-induced 17 
rotations decreased in SCS groups. Immunohistochemically, tyrosine hydroxylase 18 
(TH)-positive fibers in the striatum were significantly preserved in SCS groups. 19 
TH-positive neurons in the substantia nigra pars compacta were significantly preserved 20 
in 50Hz SCS group. The level of vascular endothelial growth factor (VEGF) was 21 
upregulated by SCS at 1 week after the lesion. These results suggest that high cervical 22 
SCS exerts neuroprotection in PD model of rats, at least partially by upregulation of 23 
VEGF. SCS is supposed to suppress or delay PD progression and might become a less 24 
3 
 
invasive option for PD patients, although further preclinical and clinical investigations 1 
are needed to confirm the effectiveness and safety.2 
4 
 
Introduction  1 
Parkinson’s disease (PD) is a progressive neurodegenerative disease caused by 2 
the loss of dopaminergic neurons in the nigrostriatal system. Levodopa treatment 3 
remains the gold standard of treatment for PD, but only supportive effects are achieved 4 
with adverse effects (e.g., dyskinesias) over time [1] necessitating the need for 5 
innovative therapies.  6 
In surgical treatment, deep brain stimulation is effective for motor symptoms of 7 
PD, but the inclusion criteria have been limited. In 2009, Fuentes and colleagues 8 
reported that spinal cord stimulation (SCS) restores locomotion in animal models of PD 9 
[2]. In the clinic, SCS is an alternative approach for treatment of neuropathic pain after 10 
medication has failed. Previously, laboratory studies have shown that SCS increases 11 
cerebral blood flow in animal models of cerebral ischemia or spasms after subarachnoid 12 
hemorrhage through vasodilation effects with subsequent behavioral amelioration 13 
[3-10], and recently, a study demonstrated that SCS at the high thoracic level for PD 14 
model of rats has neuroprotective effects [11].
  
15 
Neuroprotective effects of electrical stimulation have been demonstrated in our 16 
preclinical reports [12, 13], but the mechanisms of action remain incompletely 17 
understood. In ischemic stroke rats, neurotrophic factors (glial cell line-derived 18 
neurotrophic factor: GDNF; brain-derived neurotrophic factor: BDNF), and vascular 19 
endothelial growth factor (VEGF) were upregulated by cortical stimulation [12].
 
20 
Moreover, in PD rats, stimulation of the subthalamic nucleus generated neuroprotective 21 
effects [14-17], with BDNF implicated as a therapeutic target for the observed 22 
neuroprotection [16].
 
In the present study, we characterized behaviorally and 23 
immunohistochemically neuroprotective effects of high cervical SCS on PD rats, with 24 
5 
 
emphasis on the likely involvement of secretion of neurotrophic and growth factors as a 1 
key mechanism of action.  2 
6 
 
Materials and Methods 1 
Ethics statement 2 
 All animal procedures in this study were specifically approved by the 3 
Institutional Animal Care and Use Committee of Okayama University Graduate School 4 
of Medicine (protocol #OKU-2012311).  5 
 6 
Animals 7 
 Adult female Sprague-Dawley rats (Charles River, Japan; n=80) weighing 8 
200-250g at the beginning of the experiment were used. They were singly housed per 9 
cage in a temperature and humidity-controlled room, maintained on a 12-hour light/dark 10 
cycle, with free access to food and water. 11 
 12 
Experimental design   13 
 In order to evaluate the neuroprotective effects of high cervical SCS, rats were 14 
classified into 4 groups, namely, control group and 2, 50 and 200Hz SCS groups 15 
respectively (total 40 rats, each group n=10). All rats received the lower half of C1 and 16 
C2 laminectomy under general anesthesia with implantation of a monopolar electrode. 17 
We selected the high cervical cord as a target, because we expected that the high 18 
cervical SCS might activate upper level cord and brain stem. Subsequently rats in SCS 19 
groups received hour-long electrical stimulations daily for 16 days, but rats in control 20 
group received no electrical stimulation. At 2 days after initial SCS, 21 
6-hydroxydopamine (6-OHDA) was injected into the right striatum of all rats as 22 
described previously (see below). We started SCS at 2 days before 6-OHDA 23 
administration, because we expected the pre-conditioning effect of SCS, and stimulation 24 
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continued for 2 weeks (1hour/ day) after 6-OHDA administration in which 1 
degeneration of dopaminergic neurons is going on. For behavioral evaluations of PD 2 
symptoms, cylinder test was performed at 1 and 2 weeks after 6-OHDA injection and 3 
amphetamine-induced rotation test was performed at 2 weeks after the lesion. In detail, 4 
we conducted cylinder test just before stimulation at 1 week after 6-OHDA 5 
administration. At 2 weeks after 6-OHDA administration, cylinder test and 6 
amphetamine-induced rotation test in twelve hours after the last SCS to minimize the 7 
effects of anesthetic. 8 
 Following behavioral tests, animals were euthanized for immunohistochemical 9 
investigations. In order to evaluate the relationship between SCS and secretion of 10 
neurotrophic and growth factors, another cohort of rats was randomly assigned to one of 11 
two groups (total 40 rats: control group and 50Hz SCS group, n=20, respectively) using 12 
the corresponding procedures as described above. These experimental designs are 13 
shown in Fig. 1A and B. 14 
 15 
Implantation of an electrode  16 
 All rats were deeply anesthetized with pentobarbital (35 mg/kg, i.p.) and placed 17 
in a stereotaxic instrument (Narishige, Japan). Laminectomy of the lower half of C1 and 18 
C2 was performed. A silver ball electrode with diameter of 2 mm was implanted in the 19 
epidural space over the dorsal column. A ground electrode was placed in the skull of 20 
rats with the connection side of the electrode outside the body through the subcutaneous 21 
lead. The systems used in this study are shown in Fig. 1C and D. 22 
 23 
Electrical stimulation 24 
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 Rats in both control group and SCS groups were anesthetized with pentobarbital 1 
(10 mg/kg, i.p.) with subsequent connection of the electrode to the stimulation device 2 
(SEN-7203, NIHON KOHDE, Japan). Thereafter, rats in SCS groups received 3 
hour-long stimulations daily for 16 days. To minimize the effects of anesthesia, we used 4 
a very small amount of anesthetic, so rats were immobilized only during stimulation. 5 
We also used the 26G thin needle for injection.  6 
The parameter of stimulating pulses was adjusted to a variety of frequency (2, 7 
50, or 200Hz) based on the results of our previous studies and another basic reports 8 
demonstrating therapeutic efficacy [2, 4, 7, 12], and intensities were individually 9 
adjusted according to the 80% motor threshold intensity. After the stimulation, the 10 
electrode connection was removed, and rats were allowed to move freely. 11 
 12 
6-OHDA lesion  13 
 All rats were anesthetized with sodium pentobarbital (35 mg/kg, i.p.) and 14 
placed in a stereotaxic instrument (Narishige, Japan). Twenty μg of 6-OHDA (4 μl of 5 15 
mg/ml dissolved in saline containing 0.2 mg/ml ascorbic acid; Sigma, USA) was 16 
injected into the right striatum with a 28G Hamilton syringe. The lesion coordinates 17 
were as follows: 1 mm anterior to the bregma, 3 mm lateral to the sagittal suture, and 5 18 
mm ventral to the surface of the brain with the tooth-bar set at -3.0 mm [18]. The 19 
injection rate was 1 μl/min. After the injection, the syringe was left in place for 20 
additional 5 minutes before being it was retracted slowly (1 mm/min). 21 
 22 
Behavioral tests 23 
 Cylinder test: We performed the cylinder test, which assessed the degree of 24 
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forepaw asymmetry, at 1 and 2 weeks after 6-OHDA injection. Rats were placed in a 1 
transparent cylinder (diameter: 20 cm, height: 30 cm) for 3 minutes and the number of 2 
forepaw contacts to the cylinder wall was counted [19]. The score of cylinder test in this 3 
study was calculated as a contralateral bias, that is, [(the number of contacts with the 4 
contralateral limb)-(the number of contacts with the ipsilateral limb)/ (the number of 5 
total contacts) x100] [20].  6 
 Amphetamine-induced rotation test: All rats were tested with amphetamine (3.0 7 
mg/kg, Dainippon Sumitomo Pharma, Japan) at 2 weeks after 6-OHDA injection. The 8 
rotational behaviors were assessed for 90 minutes with a video camera. Full 360° turns 9 
ipsilateral to the lesion were counted. 10 
 11 
Immunohistochemical investigations  12 
 All rats were euthanized with an overdose of pentobarbital (100 mg/kg) at 2 13 
weeks after 6-OHDA injection, and perfused transcardially with 200 ml of cold PBS 14 
and 200 ml of 4% paraformaldehyde (PFA) in PBS. Brains were removed and 15 
post-fixed in the same fixative overnight at 4 degrees C, and subsequently stored in 30% 16 
sucrose in PBS until completely submerged. The brains were coronally sectioned at the 17 
thickness of 40 µm. Free-floating sections for TH staining were blocked by 3% 18 
hydrogen peroxide in 70% methanol for 7 minutes. Sections were washed 3 times for 5 19 
minutes in PBS. Sections were then incubated overnight at 4 degrees C with rabbit 20 
anti-TH antibody (1:500; Chemicon, Temecula, CA, USA) with 10% normal horse 21 
serum. After several rinses in PBS, sections were incubated for 1 hour in biotinylated 22 
donkey anti-rabbit IgG (1:500; Jackson Immuno-Research Lab, West Grove, PA, USA), 23 
then for 30 minutes in avidin-biotin-peroxidase complex (Vector Laboratories, 24 
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Burlingame, CA, USA). Subsequently, the sections were treated with 3, 1 
4-diaminobenzidine (DAB; Vector) and hydrogen peroxide, mounted on albumin-coated 2 
slides and embedded with cover glass. 3 
 4 
Morphological analyses  5 
 The density of TH-positive fibers in the striatum of rats was determined and 6 
analyzed with a computerized analysis system as described previously [21]. Five 7 
sections at 0.5±1.0 mm anterior to the bregma were randomly selected for quantitative 8 
analyses [18]. The two areas adjacent to the needle tract of lesioned side and the 9 
symmetrical areas in the contralateral side were analyzed, respectively. The percentages 10 
of lesion to the intact side were evaluated in each section and the averages were used for 11 
statistical analyses. The images were computer-processed into binary images using an 12 
appropriate threshold (Scion Image, Scion Corp., Frederick, MD, USA). The areas were 13 
then calculated and used for statistical analyses. According to our previous publication 14 
for counting the number of TH-positive neurons [22], every fifth 40 μm-thick coronal 15 
section through the substantia nigra pars compacta (SNc) was explored using 3 coronal 16 
sections, respectively, at 4.8, 5.3, and 5.8 mm posterior to the bregma. The number of 17 
cells was summed up in each group. The percentage to the intact side was analyzed and 18 
the average was used for the statistical analyses. 19 
 20 
ELISA Analyses  21 
 For protein assay, fresh brains from rats of control and 50Hz SCS groups were 22 
quickly harvested after decapitation of animals anesthetized with an overdose of 23 
pentobarbital (100 mg/kg, i.p.) at 1 and 2 weeks after 6-OHDA lesion. Brains were 24 
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sliced at the thickness of 2 mm. The brain tissue of the striatum was punched out using a 1 
biopsy punch (3 mm-hole, Kai corporation and Kai industries co., ltd, Japan) as shown 2 
in Fig. 1E. Brain tissues were then homogenized in T-PER (Pierce, Rockfold, IL) and 3 
centrifuged at 10,000G for 10 minutes at 4 degrees C, and the supernatant was obtained. 4 
Brain VEGF and GDNF levels were measured by the usage of rat VEGF ELISA assay 5 
kit (IBL, Japan) and rat GDNF ELISA assay kit (Abnova, Taiwan). 6 
 7 
Statistical Analyses  8 
 Cylinder test data were evaluated statistically using repeated measures of 9 
ANOVA (analysis of variance), while the data from amphetamine-induced rotation test, 10 
immunohistochemistry, and ELISA were evaluated statistically using single ANOVA, 11 
with subsequent post hoc Scheffe’s test. Statistical significance was preset at p<0.05. 12 
Mean values are presented with standard deviation (SD). 13 
 14 
Results 15 
Behavioral tests 16 
 Cylinder test: In 2Hz and 50Hz SCS groups, the treated animals appeared to 17 
perform better in the cylinder test than those in 200Hz SCS and control groups, but did 18 
not reach statistical significance at 1 and 2 weeks after 6-OHDA injection (Contralateral 19 
bias: 2Hz: 69±38.0 and 49±54.1%; 50Hz: 59±46.0 and 29±35.6%; 200Hz: 71±23.1 and 20 
83±22.5%; control group: 60±25.4 and 66±20.7%, at 1 and 2 weeks respectively; 21 
repeated-measures ANOVA; F(3, 29)=1.871, p=0.1566) (Fig. 2A).  22 
 Amphetamine-induced rotation test: The number of amphetamine-induced 23 
rotations at 2 weeks after 6-OHDA injection in animals exposed to 2Hz, 50Hz, and 24 
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200Hz SCS (2Hz: 667±344 turns/90min; 50Hz: 575±230 turns/90min; 200Hz: 759±307 1 
turns/90min respectively, Fig. 2B) decreased compared to control group (1037±192 2 
turns/90min, Fig. 2B). In addition, the number of amphetamine-induced rotations 3 
significantly decreased in the other cohort of animals exposed to 50Hz SCS compared 4 
to that in control group (ANOVA; F (3, 32)=5.212; p=0.0048; p value<0 .05). 5 
 6 
Immunohistochemical investigations  7 
 Rats in all SCS groups showed significant preservation of TH-positive fibers in 8 
the striatum (2Hz: 78±9.9%; 50Hz: 96±5.2%; 200Hz: 83±7.5% relative to the intact 9 
side, respectively, Fig. 3), compared to those in control group (64±11.1%, ANOVA; F (3, 10 
33) =20.731; p<0.0001; p value<0 .05, Fig. 3). 11 
 The rats that received 50Hz SCS also displayed significant preservation of 12 
TH-positive neurons in the SNc (66±9.2% for 50Hz SCS group relative to the intact 13 
side, ANOVA; F (3, 31) =5.155; p=0.0052; p value< 0.05, Fig. 4), compared to those in 14 
control group (44±14.4% relative to the intact side, Fig. 4).  15 
 16 
Protein assay for neurotrophic and growth factors 17 
 VEGF level of the lesioned striatum in rats that received 50Hz SCS increased 18 
compared to that of control group at 1 and 2 weeks after 6-OHDA lesion, respectively 19 
(50Hz: 35.8±7.4 pg/ml and 54.3±26.8 pg/ml; control group: 25.5±6.9 pg/ml and 20 
44.6±11.6 pg/ml at 1 and 2 weeks, respectively, Fig. 5A and B) and reached statistical 21 
significance at 1 week after 6-OHDA lesion (ANOVA; F (3, 42); p=0.0006; p 22 
value<0 .05, Fig. 5A). On the other hand, 50Hz SCS did not increase GDNF level in the 23 
striatum at 1 and 2 weeks after 6-OHDA lesion compared to that of rats in control group 24 
13 
 
(50Hz: 113.3±17.1 pg/ml and 592.4±256.3 pg/ml; control group: 99.0±32.8 pg/ml and 1 
542.5±161.3 pg/ml, at 1 and 2 weeks, respectively, Fig. 5C and D).  2 
 3 
Discussion 4 
 The present study showed that SCS exerted neuroprotective effects on PD 5 
model of rats characterized by behavioral and immunohistochemical amelioration. The 6 
neuroprotective effects of 50Hz SCS appeared optimal, compared to those of 2Hz and 7 
200Hz SCS. VEGF level increased in the lesioned striatum of rats that received 50Hz 8 
SCS, implicating that the neuroprotective effects of 50Hz SCS may partially involve a 9 
VEGF-mediated mechanism.  10 
 11 
SCS parameter 12 
 There are few reports about the effect of SCS for animal model of PD, and 13 
therefore there is almost no report that would be helpful for our choice of electrical 14 
parameter. For this reason, we had chosen the parameters referring to the report of 15 
electrical stimulation experiments for the various central nervous diseases. In the 16 
previous report about the effect for the cerebral blood flow, 50Hz SCS had the highest 17 
increasing effect of the cerebral blood flow [23]. In reference to this report, the other 18 
majority of SCS experiments about the cerebral blood flow are used 50Hz SCS. On the 19 
other hand, according to our electrical stimulation experiments on cerebral infarction 20 
model of rats, we had reported that low frequency stimulation (i.e. 2 or 10Hz) were 21 
effective for reduction of volume of cerebral infarction [12]. Furthermore, 333Hz SCS 22 
are used in the report of the effect of SCS for PD model [2]. Referring to these reports, 23 
we had selected these three stimulation frequencies (i.e. 2, 50, and 200Hz). It has been 24 
14 
 
reported that 200 or 2000Hz SCS had no increasing effect in cerebral blood flow [24]. 1 
We have considered that this result is a one of the reason why 200 Hz SCS hasn’t 2 
obtained good effect in this study. We also have impression that the 200Hz SCS might 3 
damage to rat spinal cord, and rat itself.  4 
 5 
Current status of SCS 6 
 In clinical practice, SCS was introduced in 1967 for the treatment of chronic 7 
intractable neuropathic pain [25]. Today, SCS targeting the dorsal column is clinically 8 
used as a valuable treatment for neuropathic pain, especially for failed back surgery 9 
syndrome (FBSS) [26], complex regional pain syndrome type 1 [27]. The mechanisms 10 
of pain relief have not yet been well elucidated. Previously, the gate control theory 11 
advanced the notion that pain signals from the peripheral nerve were presynaptically 12 
inhibited in the spinal cord [28]. However in recent years, other neurochemical factors 13 
and electrophysiological factors have been thought to mediate pain [29-36]. On the 14 
other hand, the increase of cerebral blood flow has been shown to accompany the 15 
therapeutic effects of SCS [37-39].
 
In animal experiments, several studies have 16 
demonstrated efficacy of SCS in models of cerebral infarction or vasospasm after 17 
subarachnoid hemorrhage [3-10]. SCS was also used for the treatment against cardiac 18 
ischemia [40], or postoperative ileus [41]. The mechanism of vasodilation by SCS 19 
appears to be related to suppression of sympathetic activity [42, 43], as well as indirect 20 
activation of the brainstem or cerebellar vasomotor centers [6, 7, 44], and/or causing the 21 
release of rapid vasoactive substances such as nitric oxide or calcitonin gene-related 22 
peptide [45-47]. Moreover, SCS was accompanied by dilation of small arteries in the 23 
subarachnoid space without visible changes of intraparenchymal vessels in diameter [4], 24 
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altogether supporting the concept of a humoral effect by SCS. Accordingly, assessment 1 
of alterations in the vascular system (i.e., monitoring VEGF levels as in the present 2 
study) may provide insights into the neuroprotective effects of SCS. 3 
 4 
Neurotrophic and growth factors and electrical stimulation 5 
 Electrical stimulation has been used in the clinical setting for various diseases 6 
of the central nervous system, including epilepsy, central pain, and psychological 7 
disorders like schizophrenia and depression. Electrical stimulation of the cerebral cortex 8 
increased the expression of neurotrophic and growth factors, such as GDNF, BDNF and 9 
VEGF [12]. Previously we demonstrated that parenchymal stimulation exhibited 10 
significant upregulation of GDNF and VEGF for chronic-phase ischemic stroke model 11 
of animals [13]. And in PD rats, stimulation of subthalamic nucleus increases BDNF in 12 
nigrostriatal system [16]. However, there is almost no report on the relationship between 13 
SCS and neurotrophic and growth factors. Very recently, Yadav and colleagues 14 
demonstrated the possibility that high thoracic SCS might have neuroprotective effects 15 
for PD model of rat, and pronounced that SCS might increase production or delivery of 16 
neurotrophic factors [11]. In our study, we demonstrated that VEGF increased in the 17 
lesioned striatum of rats that received SCS. SCS didn’t upregulate BDNF (data not 18 
shown). As previously reported, SCS may increase cerebral blood flow and enhance 19 
patency of the cerebral microvasculature [3-10], again invoking the effects of SCS on 20 
the vascular system. VEGF is known to enhance glial proliferation and angiogenesis 21 
with synergistic neuroprotective effects [48-51]. Neuroprotective effects have also been 22 
associated with neurogenesis and intrinsic neurorestoration [50, 52-53]. Furthermore, 23 
increased VEGF signaling may result in neuroprotective effects thereby enhancing the 24 
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survival of dopaminergic neurons, which suggests a potential therapeutic application for 1 
PD [49-50, 54]. Additionally, VEGF may protect dopaminergic neurons by 2 
improvement of microcirculation through enhanced angiogenesis. These multi-pronged 3 
vasculature-based neuroprotective pathways might have been elicited by the observed 4 
VEGF elevation following SCS treatment in our PD animals.  5 
 6 
SCS and Parkinson’s disease 7 
 In 2009, Fuentes and co-workers reported that SCS restores locomotion in 8 
animal models of PD [2], indicating that SCS may alleviate PD-related akinesia. It is 9 
known that neural fibers which are most activated by SCS might be the superficial 10 
fibers of the dorsal columns, although the underlying mechanisms are still not well 11 
understood. SCS may facilitate corticostriatal oscillatory mode of neuronal activity with 12 
subsequent increase of locomotion [2]. However, a clinical study showed that SCS 13 
failed to relieve akinesia or restore locomotion in PD [55]. This discrepancy may be due 14 
to the limitation of the PD model in approximating the clinical pathophysiology, as well 15 
as the differences in SCS stimulation parameters in the laboratory and the clinic. In the 16 
present study we showed that 50Hz SCS may afford neuroprotective effects on the 17 
nigrostriatal system of PD rats. Yet, it has translational limitations as patients receive 18 
SCS after PD. Yadav and colleagues demonstrated that SCS had neurorestorative effect. 19 
In their protocol, SCS started one week after 6-OHDA administration [11]. We must 20 
conduct the additional studies, which demonstrate the neurorestorative effects of SCS 21 
on PD model of rats in the future. 22 
 23 
Conclusions 24 
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 This study demonstrates that high cervical SCS exerts neuroprotective effects 1 
in PD model of rats by increasing VEGF levels in the lesioned striatum. SCS is 2 
supposed to suppress or delay PD progression. In the future, SCS may become a less 3 
invasive therapeutic option for PD patients, although further preclinical experiments are 4 
warranted to confirm the efficacy, safety, and mechanisms of action.  5 
18 
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Figure Legends  1 
Figure Legend 1. Time course and SCS electrode, and the brain region punched 2 
out for protein assay. (A) Scheme showing overall experimental design. (B) Scheme 3 
showing experimental design for protein assay. (C) Photograph showing SCS electrode 4 
used in this study (diameter: 2mm; wire length: 60mm). (D) Scheme showing a rat 5 
during stimulation. (E) Brain tissue (diameter: 3mm showing gray circle), 6 
corresponding to the striatum, was punched out from both the lesioned and the intact 7 
side. 8 
Figure Legend 2. The results of cylinder test and amphetamine-induced rotation 9 
test.  10 
(A) Rats receiving 2Hz and 50Hz SCS showed reduction of the contralateral bias at 2 11 
weeks after 6-OHDA lesion, compared to that of rats in control group. (B) The number 12 
of amphetamine-induced rotations in all SCS groups decreased, compared to that of 13 
control group. There was a significant amelioration in 50Hz SCS group, compared to 14 
control group (*p<0.05, n=10, respectively). 15 
Figure Legend 3. Tyrosine hydroxylase (TH) immunostaining in the striatum and 16 
the ratio to the intact side.  17 
(A) TH immunostaining in the striatum. Severe loss of TH-positive fibers was seen in 18 
the lesioned striatum of control group. Preservation of TH-positive fibers was seen in 19 
the lesioned striatum of all SCS groups. Scale bar: 200µm. (B) The all SCS groups 20 
showed significant preservation of TH-positive fibers in the lesioned striatum, 21 
compared to those in control group (*p<0.05, n=10, respectively). 22 
Figure Legend 4. TH immunostaining in the substantia nigra pars compacta (SNc), 23 
and the ratio to the intact side.  24 
26 
 
(A) TH immunostaining in the intact SNc. Severe loss of TH-positive neurons was seen 1 
in the lesioned side SNc of control group. Preservation of TH-positive neurons was seen 2 
at the lesioned side SNc of 50Hz SCS group. Scale bar: 200µm. (B) Significant 3 
preservation of TH-positive neurons in the lesioned-side SNc of 50Hz SCS group, 4 
compared to those of control group (*p<0.05, n=10, respectively). 5 
Figure Legend 5. Results of ELISA analysis for VEGF and GDNF.  6 
(A, B) In the lesioned striatum, VEGF was significantly increased by SCS at 1 week 7 
after 6-OHDA lesion (*p<0.05). At 2 weeks after 6-OHDA lesion, VEGF level in the 8 
lesioned striatum also appeared elevated, but did not reach statistical significance.  9 
(C, D) GDNF in the striatum of both sides was not significantly increased by SCS at 1 10 
and 2 weeks after 6-OHDA lesion. (C-lesion: control group lesioned side Striatum; 11 
C-intact: control group intact side Striatum; S-lesion: 50Hz SCS group lesioned side 12 
Striatum; S-intact: 50Hz SCS group intact side Striatum, n=10, respectively) 13 
